铝碳酸镁和莫沙必利联合治疗胆汁反流性胃炎的效果及对胃内胆汁的影响

Hydrotalcite and mosapride in treating bile reflux gastritis and its effect on intragastric bile

目的观察铝碳酸镁和莫沙必利联合治疗胆汁反流性胃炎的效果及对胃内胆汁的影响。方法选取本院2015年1月~2018年1月接收的80例胆汁反流性胃炎患者作为研究对象,按照治疗方式不同将所有患者分为实验组与对照组,每组40例。对照组患者给予多潘立酮、铝碳酸镁等常规药物治疗,实验组患者在常规给药基础上联合莫沙必利治疗,比较两组患者治疗效果以及治疗前后上腹部疼痛、恶心呕吐以及呕吐胆汁等症状评分变化情况。结果实验组好转率为95.0%,对照组好转率为82.5%,实验组患者好转率明显优于对照组,差异有统计学意义(P<0.05)。实验组患者治疗后上腹部疼痛、恶心呕吐、呕吐胆汁等症状评分均明显低于对照组,差异有统计学意义(P<0.05)。结论对于胆汁反流性胃炎患者给予铝碳酸镁联合莫沙必利治疗可有效改善患者临床症状,减少胆汁反流。

Objective To observe the effect of hydrotalcite and mosapride on bile reflux gastritis and its effect on gastric bile. Methods From January 2015 to January 2018, 80 patients with bile reflux gastritis were selected as research subjects. All patients were divided into experimental group and control group according to different treatment methods, 40 cases in each group. The patients in the control group were treated with dom- peridone and magnesium aluminum carbonate. The patients in the experimental group were treated with mosapride on the basis of conventional medication. The treatment effect of the two groups and the changes of the symptoms of upper abdominal pain, nausea and vomiting, and vomiting and bile were compared before and after the treatment. Results The improvement rate of the experimental group was 95.0%, and the improvement rate of the control group was 82.5%. The improvement rate of the patients in the experimental group was obviously better than that of the control group. The dif ference was statistically significant （P 〈 0.05）. The scores of upper abdominal pain, nausea and vomiting, vomiting and bile in the experimental group were significantly lower than those in the control group, and the difference was statistically significant （P〈0.05）. Conclusion For patients with bile reflux gastritis, the combination of magnesium hydrotalcite and Mosapride can effectively improve the clinical symptoms and reduce bile reflux.